124 related articles for article (PubMed ID: 11929806)
1. Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer.
Li Z; Meng ZH; Chandrasekaran R; Kuo WL; Collins CC; Gray JW; Dairkee SH
Cancer Res; 2002 Apr; 62(7):1939-43. PubMed ID: 11929806
[TBL] [Abstract][Full Text] [Related]
2. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.
Evron E; Umbricht CB; Korz D; Raman V; Loeb DM; Niranjan B; Buluwela L; Weitzman SA; Marks J; Sukumar S
Cancer Res; 2001 Mar; 61(6):2782-7. PubMed ID: 11289162
[TBL] [Abstract][Full Text] [Related]
3. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
4. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer.
Widschwendter M; Berger J; Daxenbichler G; Müller-Holzner E; Widschwendter A; Mayr A; Marth C; Zeimet AG
Cancer Res; 1997 Oct; 57(19):4158-61. PubMed ID: 9331065
[TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of the THRB gene in tissue and plasma of breast cancer patients.
Ling Y; Xu X; Hao J; Ling X; Du X; Liu X; Zhao X
Cancer Genet Cytogenet; 2010 Jan; 196(2):140-5. PubMed ID: 20082849
[TBL] [Abstract][Full Text] [Related]
7. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3p and breast cancer.
Yang Q; Yoshimura G; Mori I; Sakurai T; Kakudo K
J Hum Genet; 2002; 47(9):453-9. PubMed ID: 12202982
[TBL] [Abstract][Full Text] [Related]
9. Hypermethylation does not account for the frequent loss of the retinoic acid receptor beta2 in breast carcinoma.
Yang Q; Sakurai T; Yoshimura G; Mori I; Nakamura M; Nakamura Y; Suzuma T; Tamaki T; Umemura T; Kakudo K
Anticancer Res; 2001; 21(3B):1829-33. PubMed ID: 11497266
[TBL] [Abstract][Full Text] [Related]
10. Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer.
Silva JM; Domínguez G; González-Sancho JM; García JM; Silva J; García-Andrade C; Navarro A; Muñoz A; Bonilla F
Oncogene; 2002 Jun; 21(27):4307-16. PubMed ID: 12082618
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression.
Ai L; Kim WJ; Kim TY; Fields CR; Massoll NA; Robertson KD; Brown KD
Cancer Res; 2006 Aug; 66(16):7899-909. PubMed ID: 16912163
[TBL] [Abstract][Full Text] [Related]
12. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast.
Palacios J; Sarrió D; García-Macias MC; Bryant B; Sobel ME; Merino MJ
Mod Pathol; 2003 Jul; 16(7):674-8. PubMed ID: 12861063
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
Mirza S; Sharma G; Prasad CP; Parshad R; Srivastava A; Gupta SD; Ralhan R
Life Sci; 2007 Jul; 81(4):280-7. PubMed ID: 17599361
[TBL] [Abstract][Full Text] [Related]
14. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
[TBL] [Abstract][Full Text] [Related]
15. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
Umbricht CB; Evron E; Gabrielson E; Ferguson A; Marks J; Sukumar S
Oncogene; 2001 Jun; 20(26):3348-53. PubMed ID: 11423985
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
18. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.
Nass SJ; Herman JG; Gabrielson E; Iversen PW; Parl FF; Davidson NE; Graff JR
Cancer Res; 2000 Aug; 60(16):4346-8. PubMed ID: 10969774
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.
Kobatake T; Yano M; Toyooka S; Tsukuda K; Dote H; Kikuchi T; Toyota M; Ouchida M; Aoe M; Date H; Pass HI; Doihara H; Shimizu N
Oncol Rep; 2004 Nov; 12(5):1087-92. PubMed ID: 15492797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
